Kura Oncology Inc (KURA NASDAQ) stock market data APIs
$9.8384
-0.23(-2.3%)
as of October 27, 2026
Try our APIs with
free plan!
Kura Oncology Inc Financial Data Overview
Price chart is built with
Anychart
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Prev. Close
9.8384
Open
9.6123
High
9.8384
Low
9.4487
52 wk Range
7.3575-13.9
Market Cap
856 M
Shares Outstanding
88 961 K
Revenue
77 225 K
EPS
-0.77
Beta
0.469
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kura Oncology Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kura Oncology Inc data using free add-ons & libraries
Get Kura Oncology Inc Fundamental Data
Kura Oncology Inc Fundamental data includes:
- Net Revenue: 77 225 K
- EBITDA: -316 799 008
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.89
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kura Oncology Inc News
New
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
The market expects Kura Oncology (KURA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus ou...
CFOs On the Move: Week ending Sept. 11
This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. Pam Kaur | HSBC Pam Kaur, group chief financial officer of HSBC, p...
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology, Inc.(NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it i...
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology, Inc. – $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, an...
Get Kura Oncology Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.